Featured Research

from universities, journals, and other organizations

Drug Breakthrough For Psoriasis Sufferers

Date:
October 14, 2005
Source:
University of Manchester
Summary:
An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

An international team led by a dermatologist at The University ofManchester has found that treatment with the emerging drug infliximab,marketed as Remicade, can quickly and significantly improve psoriasissymptoms.

The European Infliximab for Psoriasis Efficacy and Safety Study(EXPRESS) was a placebo-controlled trial on 378 patients with moderateto severe psoriasis, to test the efficacy and safety of the drug. Thefindings, published in the 15 October issue of The Lancet, show that80% of patients achieved at least a 75% improvement in symptoms afterten weeks treatment with the drug, as opposed to just 3% of thosereceiving a placebo.

Psoriasis is a chronic condition which results when skin cellsover-produce and accumulate on the surface of the skin, producing red,scaly 'plaques' which may itch and bleed. It is thought to be geneticin origin and is a consequence of an abnormal inflammatory response inthe skin. Around 2% of the population suffer from the disease, withabout 30% of cases considered moderate to severe, but until nowtreatment options have been limited.

Infliximab blocks the activity of 'tumour necrosis factoralpha' (TNF-alpha), a protein involved in inflammation, and the vastmajority of the trial subjects treated with the drug achievedclinically-significant levels of skin clearance. Nearly 60% experiencedat least a 90% improvement in symptoms -- or near-complete skinclearance -- after ten weeks, versus 1% receiving the placebo, whilst26% achieved complete skin clearance (versus 0% receiving the placebo).The improvements continued throughout the 50-week study.

Professor Christopher Griffiths, the University academicleading the trial from the Dermatology Centre at Hope Hospital,Salford, said: "These results indicate that Infliximab is a veryeffective therapy among the newer biological treatments for psoriasis.As a dermatologist, I am very encouraged by the data, which show thatpatients with moderate to severe psoriasis can rapidly achieve skinclearance and that these results can be maintained."

Patients receiving Infliximab also experienced a good responsein nail psoriasis, which is present in 20 -- 50% of psoriasis patientsand often thought of as a treatment-resistant disease. By week 24 ofthe trial, those receiving the drug were experiencing a 56% averagedecrease in this condition, and again this response was maintainedthroughout the trial.

"Physicians' assessments of the patients' conditions backed upour findings," confirmed Professor Griffiths, "with 83% of thosereceiving the drug assessed as having minimal or cleared symptoms byweek 10 of the trial as opposed to just 4% of those receiving theplacebo."



Story Source:

The above story is based on materials provided by University of Manchester. Note: Materials may be edited for content and length.


Cite This Page:

University of Manchester. "Drug Breakthrough For Psoriasis Sufferers." ScienceDaily. ScienceDaily, 14 October 2005. <www.sciencedaily.com/releases/2005/10/051014072910.htm>.
University of Manchester. (2005, October 14). Drug Breakthrough For Psoriasis Sufferers. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2005/10/051014072910.htm
University of Manchester. "Drug Breakthrough For Psoriasis Sufferers." ScienceDaily. www.sciencedaily.com/releases/2005/10/051014072910.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins